Exact Mass: 219.1431
Exact Mass Matches: 219.1431
Found 72 metabolites which its exact mass value is equals to given mass value 219.1431,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Miglustat
Miglustat is a drug used to treat Gaucher disease. It inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids. It is only used for patients who cannot be treated with enzyme replacement therapy with imiglucerase. It is marketed under the trade name Zavesca. Miglustat is now the first and only approved therapy for patients with Niemann-Pick disease type C (NP-C). It has recently been approved for treatment of progressive neurological symptoms in adult and pediatric patients in the European Union, Brazil, and South Korea. A - Alimentary tract and metabolism > A16 - Other alimentary tract and metabolism products > A16A - Other alimentary tract and metabolism products > A16AX - Various alimentary tract and metabolism products D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents D007004 - Hypoglycemic Agents > D065089 - Glycoside Hydrolase Inhibitors C471 - Enzyme Inhibitor > C2846 - Glucosidase Inhibitor D004791 - Enzyme Inhibitors
1-hydroperoxy-8-carboxyoctyl-3,4-epoxynon-(2E)-enyl-ether
1-hydroperoxy-8-carboxyoctyl-3,4-epoxynon-(2E)-enyl-ether is considered to be practically insoluble (in water) and basic
3-[2-(Morpholinomethyl)-1H-pyrrol-1-yl]propanenitrile
1-Propanamine, 3-(1H-indazol-3-yloxy)-N,N-dimethyl-
2-Hydroxymethyl-5-(1-hydroxypentyl)-3,4-pyrrolidinediol
miglustat
A - Alimentary tract and metabolism > A16 - Other alimentary tract and metabolism products > A16A - Other alimentary tract and metabolism products > A16AX - Various alimentary tract and metabolism products D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents D007004 - Hypoglycemic Agents > D065089 - Glycoside Hydrolase Inhibitors C471 - Enzyme Inhibitor > C2846 - Glucosidase Inhibitor D004791 - Enzyme Inhibitors
pyrrolidin-1-yl(4,5,6,7-tetrahydro-3H-benzimidazol-5-yl)methanone
(S)-TERT-BUTYL (1,5-DIHYDROXYPENTAN-2-YL)CARBAMATE
1-METHYL-4-(PIPERIDIN-4-YL)PIPERAZINE HYDROCHLORIDE
4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
PIPERIDINE-4-CARBOXYLIC ACID (4-METHYL-PYRIDIN-2-YL)-AMIDE
PIPERIDINE-3-CARBOXYLIC ACID (6-METHYL-PYRIDIN-2-YL)-AMIDE
PIPERIDINE-4-CARBOXYLIC ACID (6-METHYL-PYRIDIN-2-YL)-AMIDE
PIPERIDINE-4-CARBOXYLIC ACID (5-METHYL-PYRIDIN-2-YL)-AMIDE
PIPERIDINE-3-CARBOXYLIC ACID (4-METHYL-PYRIDIN-2-YL)-AMIDE
8,8-Dimethyl-9-oxa-2-azaspiro[5.5]undecane hydrochloride (1:1)
2-[(diethylamino)methyl]cyclohexanone hydrochloride
(6-AMINOPYRIDIN-2-YL)(1-METHYLPIPERIDIN-4-YL)METHANONE
2-(2-Hydroxyethylamino)-1,6,7-trimethylbenzimidazole
3-Butyl-1,2-dimethyl-1H-imidazol-3-ium dicyanoazanide
Lucerastat
C471 - Enzyme Inhibitor Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS). Lucerastat has the potential for Fabry disease study[1][2].
6-c-butyl-dmdp
{"Ingredient_id": "HBIN012289","Ingredient_name": "6-c-butyl-dmdp","Alias": "NA","Ingredient_formula": "C10H21NO4","Ingredient_Smile": "CCCCC(C1C(C(C(N1)CO)O)O)O","Ingredient_weight": "219.28 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "2792","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "10443411","DrugBank_id": "NA"}
